Skip to content

Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition

Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00181753
Enrollment
0
Registered
2005-09-16
Start date
2009-11-30
Completion date
2010-10-31
Last updated
2017-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Keywords

glutamine metabolic kinetics, glutamate metabolic kinetics, enteral nutrition, parenteral nutrition, burn injury, stable isotopes

Brief summary

The purpose of the study is to understand how the body uses amino acids in burned patients during the time they cannot eat normally. Amino acids occur naturally in the body and the food we eat. The body combines amino acids to make protein. It uses the proteins to do things such as heal wounds, fight infection, and provide energy. We are studying two ways of receiving nutrition: through a vein or through a tube. We are also studying two different types of food: with or without glutamine. The results of this study will be used to determine the best type and way to supply nutrients during a severe burn injury. We hope to learn how to help the body use nutrients more efficiently to better repair wounded tissues and recover earlier from injury.

Detailed description

We hypothesize that: 1. Burn patients will experience an increased conversion of glutamine to glutamate and a decreased conversion of glutamate to glutamine as compared to healthy subjects. The net direction is from glutamine to glutamate in burn patients and would render glutamine as a conditionally essential amino acid. 2. Because of the limited ability of liver to oxidize glutamate, it is possible that large doses of glutamine may cause increased gluconeogenesis in burn patients, thus aggravating the glucose homeostasis secondary to insulin resistance. 3. Enterally and parenterally fed glutamine and glutamate have different metabolic fate in the splanchnic bed and peripheral regions, therefore the doses should be tailored according to the route of administration. This study, using stable isotope tracers, aims to track the metabolic fate of glutamine and glutamate in body with the goal of enhancing nutritional efficiency.

Interventions

DRUGstandard vs. glutamine enteral or parenteral feeding.

Patient in each group will continue on the same diet for \> 3 days before we conduct stable isotope tracer measurements.

DIETARY_SUPPLEMENTStable isotope tracer study

7 hours of primed constant infusion

DIETARY_SUPPLEMENTStable isotope study

7 hours of primed constant infusion of stable isotope tracers.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* One or more of the following: * 5% Total Body Surface Area Thermal Burn * Inhalation Injury * Resting Energy Expenditure of \>15% of the predicted Basal Metabolic Rate Using Harris-Benedict. * Receiving Enteral or Parental Nutritional Support

Exclusion criteria

* Pre-existing: * Thyroid disease * Congestive Heart Failure (Ejection fraction \<20%) * Malignancy currently under treatment * Medical conditions requiring glucocorticoid treatment * Decision not to treat because of severity of injury * Presence of Anoxic brain injury with no expectation for recovery * Self-Inflicted thermal injury * Ileus, gut paralysis, or facial injuries * No NG or OG tube as part of their clinical care

Design outcomes

Primary

MeasureTime frame
This is a nutritional study. The primary outcome is to measure the protein kinetics for metabolism of the amino acid, glutamate and glutamine. Fate will be determine from measurements of subject blood and air samples.3 days and above

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026